Clinical Research Unit (CRU) – The Montreal Neurological Institute (MNI)
The MNI is one of the world’s leading institutions dedicated to clinical and basic research in neuroscience. The CRU specializes in conducting clinical trials for neurological diseases. It has been doing so since 1986, and was a major participant in the trials that led to the first approved medications for Multiple Sclerosis.
The CRU is dedicated to:
- Aiding the advancement of neuroscience through clinical research;
- participating in clinical trials to identify new or more effective treatments;
- supplying study subjects with the best quality of care; and
- providing high quality data to sponsors and investigators.
The CRU’s experience includes trials for neurological diseases such as Multiple Sclerosis, Amyotrophic Lateral Sclerosis, epilepsy, Parkinson's Disease, stroke, neuromuscular diseases, brain tumours, neuropathic pain and migraines. Furthermore, the CRU has access to the most advanced medical technologies available today.
- Phase I, II, III and IV studies;
- access to the McConnell Brain Imaging Centre, one of the largest of its kind in the world; and
- study results accepted by Health Canada, the FDA and the EMEA.
For more information on clinical trials currently underway, please see Clinical Research Unit.